Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
526139 On Other Exchanges
Symbol
Exchange
526139 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

transgene biotek ltd (526139) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TRANSGENE BIOTEK LTD (526139)

Related News

No related news articles were found.

transgene biotek ltd (526139) Related Businessweek News

No Related Businessweek News Found

transgene biotek ltd (526139) Details

Transgene Biotek Limited, a biotechnology company, engages in the research and development of vaccines in India. The company offers TrabiDHA, an omega-3 fatty acid in oil, powder, and capsule forms; and Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs. Its product pipeline includes TBL-0404, a liver caner drug; TBL-0905, a breast cancer drug; TBL-0306C, a colon cancer drug; TBL-0306M, a multiple myeloma drug; TBL-0306L, a non hodgkins lymphoma drug; and TBL-0805E, a esophageal cancer drug. The company’s product pipeline also comprises TBL-1203HI, a HIV drug; TBL-1108MS, a multiple sclerosis drug; TBL-1002OI, a oral delivery of insulin; TBL-1003AB, a oral delivery of mAbs; and TBL-1004HI, a oral delivery of HIV drug. In addition, it provides medical diagnostic services. Transgene Biotek Limited was incorporated in 1990 and is based in Medak, India.

Founded in 1990

transgene biotek ltd (526139) Top Compensated Officers

Chairman, Managing Director, Compliance Offic...
Total Annual Compensation: 1.5M
Compensation as of Fiscal Year 2014.

transgene biotek ltd (526139) Key Developments

Transgene Biotek Ltd. expected to report Q1 2016 results on August 29, 2015. This event was calculated by Capital IQ (Created on August 23, 2015).

Transgene Biotek Ltd. expected to report Q1 2016 results on August 29, 2015. This event was calculated by Capital IQ (Created on August 23, 2015).

Transgene Biotek Ltd., Board Meeting, Aug 14, 2015

Transgene Biotek Ltd., Board Meeting, Aug 14, 2015. Agenda: To consider quarterly results.

Transgene Biotek Ltd Appoints K. Koteswara Rao as Compliance Officer

Transgene Biotek Ltd. announced that Dr. K. Koteswara Rao has been appointed as the new Compliance officer of the company with immediate effect.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TB:IN 3.26 INR 0.00

526139 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 526139.
View Industry Companies
 

Industry Analysis

526139

Industry Average

Valuation 526139 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRANSGENE BIOTEK LTD, please visit www.transgenebiotek.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.